We are pleased to announce the appointment of David Passov, MBA, as our new Chief Executive Officer, effective 21st February 2025. David Passov brings extensive leadership experience in life sciences and clinical research, having successfully led large-scale operations and strategic growth initiatives across global markets. With a strong track record in business expansion, strategy and operational excellence, he is well-positioned to lead us into the next phase of organic growth and strategic acquisitions, while enhancing our service offerings and global operations.
Interim Leadership Transition
During the transition period from January 2025, Audrius Sveikata, MD, PhD., Co-Founder and Board Member, provided strong leadership and guidance as Interim CEO, ensuring continuity while the Board finalized the selection of our next CEO. We extend our deepest appreciation for Audrius’ commitment to maintaining the company’s strategic direction. As we move forward, he will continue contributing at a strategic level as a Board Member, further supporting the company’s long-term vision.
Statements from Leadership
Reflecting on the transition, Audrius Sveikata stated:
“Leading Biomapas during this period has been an honour. With David Passov now stepping in, I am confident that the company is in excellent hands. His leadership and experience will be invaluable in driving our continued growth and innovation. I look forward to supporting him and the company in my ongoing role as a Board Member.”
Alexander Winterling, Chair of the Board, added:
“We are thrilled to welcome David as our new CEO. His proven track record in leading organizations through growth, strategic expansion, and M&A integration aligns perfectly with our vision for the future. We believe he will be instrumental in taking Biomapas to the next level.”
Sharing this enthusiasm, David Passov said:
“I am very honoured to join Biomapas to help advance the company’s mission of enhancing human lives by delivering new medicines to those in need and ensuring patient safety. Given the recent strategic relationship with Carbyne Equity Partners, I look forward to working with the Board, the leadership team and our talented employees on continued global expansion and enabling our customers to benefit from our diversified offerings, operational excellence, flexibility, and reliability Biomapas is known for.“
Looking Ahead
As we embark on this next phase, our focus remains on innovation, expanding our global presence, and strengthening our operational and service capabilities. We are excited for the future and confident that David’s leadership will guide us toward even greater success.
